Tandem Diabetes Care TNDM United States — Sales
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's united states — sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's united states — sales?
- Tandem Diabetes Care (TNDM) reported united states — sales of $160.84M in Q1 2026.
- How has Tandem Diabetes Care's united states — sales changed year-over-year?
- Tandem Diabetes Care's united states — sales increased by 6.8% year-over-year, from $150.63M to $160.84M.
- What is the long-term trend for Tandem Diabetes Care's united states — sales?
- Over 4 years (2021 to 2025), Tandem Diabetes Care's united states — sales has grown at a 7.7% compound annual growth rate (CAGR), from $524.91M to $706.94M.
- What does united states — sales mean?
- This metric represents the total revenue generated from the sale of medical devices and related supplies within the United States geographic market. It serves as a primary indicator of market penetration and demand for the company's insulin delivery technology in its largest operating region. Tracking this figure helps investors assess the company's ability to maintain its competitive position and capture market share within the domestic healthcare landscape.